February 20, 2026 CEO INTRODUCTION Antoine de Saint-Affrique Chief Executive Officer INFANT MILK FORMULA UPDATE 3 ANOTHER YEAR OF QUALITY DELIVERY IN LINE WITH OUR BUSINESS MODEL Volume/mix Recurring operating margin +3.0% -0.8% -0.4% FY 22 FY 23…
February 20, 2026
CEO INTRODUCTION
Antoine de Saint-Affrique
Chief Executive Officer
INFANT MILK FORMULA UPDATE
3
ANOTHER YEAR OF QUALITY DELIVERY
IN LINE WITH OUR BUSINESS MODEL
Volume/mix
Recurring operating margin
+3.0%
-0.8%
-0.4%
FY 22
FY 23
FY 24
+2.7%
FY 25
Free Cash Flow
€2.1 bn
FY 22
€2.6 bn
12.2%
FY 22
12.6%
13.0%
€2.8 bn
13.4%
€3.80
€3.43
FY 23
FY 24
ROIC
€3.0 bn
Recurring EPS
FY 25
FY 22
€3.54
FY 23
€3.63
FY 24
FY 25
10.7%
9.5%
10.0%
8.9%
FY 23
FY 24
FY 25
FY 22
FY 23
FY 24
FY 25
Worldwide certification
CDP ‘Triple A’ list
achieved in 2025
4
HEALTH TRENDS COMING OUR WAY
UNIQUELY POSITIONED IN STRUCTURALLY GROWING CATEGORIES
Danone categories growing
faster than F&B1
Total Food Danone Total Food Danone
& Bev categories
& Bev categories
Volume L3M
Increasing healthdriven consumer
choices
Soaring demand for
protein and fibers
Proven impact of
medical nutrition
“Health” is mentioned by
Among Americans,
Malnutrition affects
7 out of 10
up~70%
to 70% up to 70%
people as part of the
reasons why they
consume yogurt2
are actively trying to
consume protein and
fibers, and 23% follow
a high-protein diet3
of people with cancer,
reducing treatment
success4
Value L3M
- Nielsen Scantrack and Danone RMS universe L3M to end November 2025; 2. IFOP survey (June 2025) conducted among a sample of around 1,000 individuals, representative of the population aged 18
and over in France, Spain, the United Kingdom, the United States, Japan, Morocco, Argentina, and Mexico; 3. IFIC Food Nutrition Survey 2025: IFIC-FH-Survey-Food-Nutrition.pdf; 4.Ryan AM, et al. 2019,
Malnutrition in Cancer: More than Just a Side Effect;
5
MULTI-ENGINE GROWTH MODEL POWERING FY25 PERFORMANCE
+4.5% LFL GROWTH, DEMONSTRATING A RESILIENT BUSINESS MODEL
Fast growing, diversified platforms
High Protein
Infant Milk Formula
Gut Health and Fibers
Medical Nutrition
Note: HSD = high-single-digit, DD = double-digit
Underpinned by a portfolio of
billion-euro brands delivering HSD to
DD growth in FY25
6
DEPLOYING RENEW CHAPTER 2 AT PACE
TRANSFORMING WHILE PERFORMING
Pivoting how we view our categories
Broadening our channel base
Shaping the future of nutrition with science -based
Double digit growth in Specialised channels1,
innovation - making healthy the easy choice
- Including pharmacies, hospitals and homecare
leveraging our consumer and patient care approach
7
FOCUSING ON EXECUTION AND COMPETITIVENESS
ENHANCING OUR ABILITY TO SEIZE OPPORTUNITIES
Strengthening capabilities across the board
Confronting underperformance while
broadening our reach
Driving digitalization from the shop floor to the
Win beyond protein and drive category leadership in
shelf
the U.S.
8
BUILDING DISTINCTIVE CAPABILITIES WHERE IT MATTERS
CREATING LONG-TERM SUSTAINABLE ADVANTAGE
Strengthening supply chain
resilience
Building differentiation
through science and IP
Investing in skills and
leadership
Danone Milk Academy, first-of-
Investing in fundamental science to
Driving accountability and
its-kind multi-year programme
create proprietary differentiation
performance
9
SHAPING OUR PORTFOLIO FOR THE FUTURE
DRIVING SCALABLE PERFORMANCE
Accelerating scale in U.S. medical
nutrition
Consolidating our dairy position in
Australia1
- Danone acquired on February 12, 2026, an additional 1% stake in its Australian Dairy joint-venture with Saputo after exercising its call option, bringing its ownership up to 51%. This will result in the
financial consolidation of this business.
10
FINANCIAL
HIGHLIGHTS
Juergen Esser
Chief Financial Officer
STRONG END TO THE YEAR 2025 WITH +4.7% LFL SALES GROWTH IN Q4
LFL GROWTH CONSISTENTLY DRIVEN BY VOLUME/MIX
+4.3%
+4.1%
+4.8%
+4.7%
+2.1%
+4.2%
Vol/mix
+4.5%
+2.5%
FY 2025
LFL sales growth
Q1 25
Note: all data in like-for-like
Price
Q2 25
Q3 25
Q4 25
12
BROAD-BASED QUALITY GROWTH IN 2025
LFL GROWTH IN ALL REGIONS AND CATEGORIES
EUROPE
+4.5%
FY 2025
LFL sales growth
Note: all data in like-for-like
+2.3%
NORTH AMERICA
+2.0%
CHINA, NORTH ASIA & OCEANIA
+11.7%
LATIN AMERICA
+6.0%
AMEA
+5.6%
+3.5%
+7.4%
+1.9%
13
FY SALES BRIDGE
STRONG LFL GROWTH; FOREX REFLECTING EURO APPRECIATION
LFL GROWTH: +4.5%
+2.7%
+1.8%
€27,376m
-4.4%
€27,283m
-0.4%
of which
-4.2% from
currencies
REPORTED GROWTH: -0.3%
FY 2024
Sales
- Includes IAS 29
Volume/mix
Price
Currency,
contribution of
hyperinflation and others 1
Scope
FY 2025
Sales
14
EUROPE
SUSTAINED MOMENTUM, WITH 9 CONSECUTIVE QUARTERS OF POSITIVE VOLUME/MIX
Q4 2025: +2.5% LFL | +1.0% vol/mix; +1.5% price
FY 2025 KEY FIGURES
• Solid performance in Plant-based and Dairy, with
continued double-digit growth in High Protein. Activia
back to growth, across the region
• Specialized Nutrition driven by strong performance in
Adult Medical Nutrition
• Strong momentum in Waters
LFL SALES GROWTH BY QUARTER
Sales
€9.8bn
Like-for-like sales growth
+2.3%
+2.0%
Q1 25
+2.2%
Q2 25
+2.6%
+2.5%
Q3 25
Q4 25
Volume/mix | price
+1.9% | +0.5%
Recurring Operating Margin
12.0%
Reported change
+10 bps
+2.3%
FY 25
15
NORTH AMERICA
MORE TO DO TO WIN OUTSIDE PROTEIN AND SPECIALIZED NUTRITION
Q4 2025: +0.7% LFL | -0.5% vol/mix; +1.3% price
FY 2025 KEY FIGURES
• Continued double-digit growth in High Protein; Remaining
yogurt portfolio work in progress
• Progressively regaining competitiveness in Coffee
Creamers; entering ‘clean label’. STōK thriving
• Strong performance in Specialized Nutrition, in both Kate
Farms and legacy Nutricia businesses
LFL SALES GROWTH BY QUARTER
Sales
€6.3bn
Like-for-like sales growth
+2.0%
Volume/mix | price
Recurring Operating Margin
Reported change
+0.6% | +1.4%
11.0%
-39 bps
+3.7%
+2.3%
+2.0%
+1.5%
+0.7%
Q1 25
Q2 25
Q3 25
Q4 25
FY 25
16
CHINA, NORTH ASIA & OCEANIA
CLOSING A YEAR OF EXCEPTIONAL PERFORMANCE WITH STRONG Q4
Q4 2025: +10.4% LFL | +10.6% vol/mix; -0.2% price
FY 2025 KEY FIGURES
• Continued strong growth in Specialized Nutrition, in
both IMF and Medical Nutrition
Sales
€4.0bn
Like-for-like sales growth
+11.7%
• Remarkable performance in EDP Japan, led by
functional brands Activia and Oikos
Volume/mix | price
• Preparing Mizone for 2026 season after a solid 2025
+12.4% | -0.7%
Recurring Operating Margin
29.2%
Reported change
-19 bps
LFL SALES GROWTH BY QUARTER
+12.4%
+13.8%
+10.4%
+9.9%
Q1 25
Q2 25
Q3 25
Q4 25
+11.7%
FY 25
17
LATIN AMERICA
STRONG END TO THE YEAR
Q4 2025: +8.3% LFL | +0.1% vol/mix; +8.2% price
FY 2025 KEY FIGURES
• Strong competitive growth in EDP, across the region,
driven by the Danone brand and High Protein
Sales
€2.8bn
Like-for-like sales growth
+6.0%
• Continued strong momentum in Specialized Nutrition
driven by double-digit growth in Aptamil and medical
Volume/mix | price
• Waters back to growth after challenging 2025 season
Recurring Operating Margin
Reported change
-1.8% | +7.8%
6.4%
+267 bps
LFL SALES GROWTH BY QUARTER
+9.0%
+8.3%
+6.0%
+2.9%
Q1 25
Q2 25
+4.3%
Q3 25
Q4 25
FY 25
18
AMEA
STRONG VOLUME/MIX LED GROWTH, DRIVEN BY SPECIALIZED NUTRITION AND EDP
Q4 2025: +8.3% LFL | +5.5% vol/mix; +2.8% price
FY 2025 KEY FIGURES
• Sustained momentum in EDP, with positive volume/mix
in Dairy Africa
Sales
€4.4bn
Like-for-like sales growth
+5.6%
• Double-digit growth in Specialized Nutrition, driven by
Aptamil across geographies, including strong
competitive growth in India
Volume/mix | price
+2.1% | +3.5%
Recurring Operating Margin
10.4%
Reported change
-2 bps
LFL SALES GROWTH BY QUARTER
+6.8%
+3.3%
Q1 25
+8.3%
+5.6%
+4.1%
Q2 25
Q3 25
Q4 25
FY 25
19
RECURRING OPERATING MARGIN UP +44 BPS IN FY 2025
FURTHER EXPANSION IN MARGIN FROM OPERATIONS
+77 bps
13.0%
-59 bps
+29 bps
13.4%
Others 1
FY 2025
Recurring
operating margin
-3 bps
REPORTED CHANGE: +44 BPS
FY 2024
Recurring
operating margin
Margin from operations
Reinvestment in
products, A&P,
capabilities
Overheads before
reinvestments
- Includes FX, IAS 29, contribution of hyperinflation, scope, and effects from other income and expenses
20
RECURRING EPS UP +4.6% IN FY 2025
DRIVEN BY OPERATIONAL PERFORMANCE
+5.9%
+0.3%
-0.6%
€3.63
-0.6%
€3.80
-0.4%
of which
-3.2% from
currencies
RECURRING EPS GROWTH : +4.6%
FY 2024
Recurring EPS
- Includes IAS 29
Operational
performance
Financing
Scope
Tax, Equity
accounted
companies,
minorities
Currency and others 1
FY 2025
Recurring EPS
21
DISCIPLINED AND RETURN-ORIENTED CAPITAL ALLOCATION
DRIVING SUSTAINABLE VALUE CREATION AND SHAREHOLDER RETURN
Free cash flow
Net debt
€2.8bn
FY 23
-€8.6 bn
+€0.1 bn
vs. FY24
Working Capital
-10.2% -163bps
of sales
improvement
vs. FY24
Dividend per share
10.7%
FY 25
€2.25
10.0%
9.5%
Capex
€1.1 bn
FY 24
ROIC
€2.15
€2.10
-€8.4 bn
FY 23
FY 24
FY 25
FY 24
FY 23
-€10.2 bn
Net debt / EBITDA
Progress
2.0x
+62bps
in FY25
- Dividend to be proposed at the Annual Shareholder’s meeting of April 23, 2026 divided by 2025 Recurring EPS
FY 25
Payout ratio
FY25
59% instable
vs. FY24
1
vs. FY24
22
2026 GUIDANCE
IN LINE WITH MID-TERM AMBITION
LFL sales growth
+3% to +5%
Recurring operating income
Growing faster
than sales
23
CEO CONCLUSION
Antoine de Saint-Affrique
Chief Executive Officer
CONCLUSION
Perform and transform
Delivering consistently, and
constructively dissatisfied
Resilient amid persistent
volatility
25
QUESTIONS &
ANSWERS SESSION
APPENDIX
Q4 2025 SALES BY GEOGRAPHICAL ZONE
EUROPE
NORTH
AMERICA
CHINA, NORTH
ASIA & OCEANIA
LATIN
AMERICA
AMEA
COMPANY
Q4 sales
€2, 404m
€1,560m
€904m
€723m
€1,093m
€6,684m
Like-for-like growth
+2.5%
+0.7%
+10.4%
+8.3%
+8.3%
+4.7%
Volume/mix
+1.0%
-0.5%
+10.6%
+0.1%
+5.5%
+2.5%
Price
+1.5%
+1.3%
-0.2%
+8.2%
+2.8%
+2.1%
28
Q4 2025 SALES BY CATEGORY
COMPANY
Q4 sales
€3,288m
€2,372m
€1,023m
€6,684m
Like-for-like growth
+3.8%
+7.2%
+2.2%
+4.7%
Volume/mix
+1.6%
+5.4%
-0.5%
+2.5%
Price
+2.2%
+1.8%
+2.7%
+2.1%
29
Q4 2025 SALES BY CATEGORY AND GEOGRAPHY
EUROPE
NORTH
AMERICA
CHINA, NORTH
ASIA & OCEANIA
AMEA &
LATIN AMERICA
COMPANY
EDP
Sales
€1,102m
€1,355m
€103m
€728m
€3,288m
LFL growth
+3.0%
+0.3%
+19.5%
+10.3%
+3.8%
Sales
€818m
€139m
€721m
€695m
€2,372m
LFL growth
+0.6%
+10.3%
+10.4%
+11.3%
+7.2%
Sales
€484m
€66m
€81m
€393m
€1,023m
LFL growth
+4.8%
-1.6%
+0.1%
+0.4%
+2.2%
COMPANY
Sales
€2,404m
€1,560m
€904m
€1,816m
€6,684m
LFL growth
+2.5%
+0.7%
+10.4%
+8.3%
+4.7%
SPECIALIZED NUTRITION
WATERS
30
FY 2025 SALES BY GEOGRAPHICAL ZONE
EUROPE
NORTH
AMERICA
CHINA, NORTH
ASIA & OCEANIA
LATIN
AMERICA
AMEA
COMPANY
FY sales
€9,779m
€6,316m
€3,953m
€2,792m
€4,444m
€27,283m
Like-for-like growth
+2.3%
+2.0%
+11.7%
+6.0%
+5.6%
+4.5%
Volume/mix
+1.9%
+0.6%
+12.4%
-1.8%
+2.1%
+2.7%
Price
+0.5%
+1.4%
-0.7%
+7.8%
+3.5%
+1.8%
31
FY 2025 SALES BY CATEGORY
COMPANY
FY sales
€13,158m
€9,277m
€4,848m
€27,283m
Like-for-like growth
+3.5%
+7.4%
+1.9%
+4.5%
Volume/mix
+1.7%
+5.5%
+0.3%
+2.7%
Price
+1.7%
+1.9%
+1.5%
+1.8%
32
FY 2025 SALES BY CATEGORY AND GEOGRAPHY
EUROPE
NORTH
AMERICA
CHINA, NORTH
ASIA & OCEANIA
AMEA &
LATIN AMERICA
COMPANY
EDP
Sales
€4,394m
€5,554m
€407m
€2,803m
€13,158m
LFL growth
+2.0%
+1.7%
+12.8%
+8.5%
+3.5%
Sales
€3,217m
€464m
€2,768m
€2,828m
€9,277m
LFL growth
+2.1%
+6.6%
+13.2%
+8.1%
+7.4%
Sales
€2,168m
€299m
€777m
€1,605m
€4,848m
LFL growth
+3.3%
+2.6%
+6.1%
-1.9%
+1.9%
COMPANY
Sales
€9,779m
€6,316m
€3,953m
€7,236m
€27,283m
LFL growth
+2.3%
+2.0%
+11.7%
+5.8%
+4.5%
SPECIALIZED NUTRITION
WATERS
33
Q4 AND FY 2025 SALES BY GEOGRAPHICAL ZONE
Q4 2025
EUROPE
NORTH AMERICA
CHINA, NORTH
ASIA & OCEANIA
LATIN
AMERICA
AMEA
TOTAL
Like-for-like sales growth
+2.5%
+0.7%
+10.4%
+8.3%
+8.3%
+4.7%
Scope
+0.1%
+3.1%
0.0%
0.0%
0.0%
+0.8%
Currency and others1
-0.7%
-8.5%
-8.3%
-10.3%
-11.3%
-6.3%
IAS 29 impact
0.0%
0.0%
0.0%
-0.1%
+0.3%
0.0%
Hyperinflation contribution
0.0%
0.0%
0.0%
+1.9%
+1.0%
+0.4%
Reported sales growth
+1.9%
-4.7%
+2.1%
-0.1%
-1.7%
-0.5%
FY 2025
EUROPE
NORTH AMERICA
CHINA, NORTH
ASIA & OCEANIA
LATIN
AMERICA
AMEA
TOTAL
Like-for-like sales growth
+2.3%
+2.0%
+11.7%
+6.0%
+5.6%
+4.5%
Scope
0.0%
-1.5%
0.0%
0.0%
0.0%
-0.4%
Currency and others1
-0.1%
-4.5%
-4.7%
-13.6%
-7.3%
-4.4%
IAS 29 impact
0.0%
0.0%
0.0%
-3.9%
-0.9%
-0.6%
Hyperinflation contribution
0.0%
0.0%
0.0%
+3.7%
+1.2%
+0.6%
Reported sales growth
+2.2%
-4.0%
+7.0%
-7.8%
-1.4%
-0.3%
1 Excluding IAS 29
34
CHANGES IN EXCHANGE RATES
% total FY 25
FY 25 vs. FY 24 (avg)
Q4 25 vs. Q4 24 (avg)
United States Dollar
21.6%
-4.2%
-8.1%
Chinese Renminbi
12.1%
-4.1%
-7.1%
British Pound
5.6%
-1.2%
-5.1%
Indonesian Rupiah
5.0%
-7.8%
-13.0%
Mexican Pesos
4.9%
-8.5%
+3.0%
Polish Zloty
3.0%
+1.6%
+1.6%
Canadian Dollar
2.8%
-6.1%
-8.1%
Brazilian Real
2.8%
-7.6%
-1.5%
Argentine Peso
2.2%
-29.9%
-35.0%
Turkish Lira
2.0%
-20.7%
-25.0%
Moroccan Dirham
1.9%
+2.0%
-1.2%
Japanese Yen
1.5%
-3.0%
-8.9%
35
RECURRING OPERATING MARGIN
FY 2024
FY 2025
€m
margin (%)
€m
margin (%)
Margin
reported change
Europe
1,143
11.9%
1,178
12.0%
+10 bps
North America
749
11.4%
694
11.0%
-39 bps
China, North Asia & Oceania
1,086
29.4%
1,154
29.2%
-19 bps
Latin America
113
3.7%
179
6.4%
+267 bps
AMEA
468
10.4%
460
10.4%
-2 bps
Essential Dairy & Plant-based
1,142
8.5%
1,121
8.5%
+4 bps
Specialized Nutrition
1,842
20.6%
2,016
21.7%
+112 bps
Waters
574
11.5%
528
10.9%
-64 bps
Total
3,558
13.0%
3,665
13.4%
+44 bps
36
RECURRING P&L
€ million
FY 2024
FY 2025
Sales
27,376
27,283
Recurring operating income
3,558
3,665
Recurring operating margin
13.0%
13.4%
Cost of net financial debt
(197)
(197)
Other recurring financial income and expense
(108)
(111)
Recurring income before taxes
3,253
3,357
Recurring income tax
(888)
(906)
Recurring effective tax rate
27.3%
27.0%
Recurring net income from fully consolidated companies
2,365
2,450
Recurring share of profit (loss) of equity-accounted companies
76
108
Recurring net income from non-controlling interests
96
97
Recurring net income group share
2,345
2,461
Recurring EPS (€)
3.63
3.80
37
NON-RECURRING NET INCOME
NON-RECURRING ITEMS
€ million
FY 2024
FY 2025
Change
Recurring net income group share
2,345
2,461
+116
Non-recurring net income group share
(324)
(636)
-312
Operating income
(179)
(725)
-546
Total Financial expenses
(75)
(96)
-21
Income tax
(41)
166
+207
Share of profit (loss) of equityaccounted companies
(46)
(16)
+30
Non-controlling interests
(17)
(34)
-17
Total net income group share
2,021
1,825
-197
38
EBITDA CALCULATION
€ million
FY 2024
FY 2025
Operating income
3,379
2,940
Depreciation, amortization and impairment of property, plant and
equipment and intangible assets
1,168
1,355
EBITDA
4,546
4,295
39
TAX DEVELOPMENT
€ million
FY 2024
FY 2025
Total income tax (reported)
(929)
(741)
Reported tax rate
31.0%
29.2%
Non-current income tax
(41)
166
Recurring income tax
(888)
(906)
Underlying tax rate
27.3%
27.0%
FY 2024
FY 2025
(766)
(697)
Income tax payments during the year
40
FREE CASH FLOW BRIDGE
€ million
FY 2024
FY 2025
Change
Recurring operating income
3,558
3,665
+107
Recurring financial result
(305)
(308)
(4)
Recurring income tax
(888)
(906)
(18)
D&A and other non-cash items1
+1,293
+1,272
(21)
Transformation projects and other cash items2
(266)
(145)
+121
Capital Expenditure
(923)
(1,055)
(132)
Change in Working Capital
+534
+276
(258)
Free Cash Flow3
3,003
2,799
(204)
- Other non cash items are not significant; 2. Transformation projects, and mainly proceeds on disposals and dividends received from equity-accounted entities;
- Alternative performance measures not defined by IFRS
41
BALANCE SHEET
€ million
ASSETS1
31/12/24
Intangible assets
Other assets
Working capital
24 009
LIABILITIES
31/12/25
31/12/24
31/12/25
17,853
16,970
8 601
8 431
Net debt2
3,718
3,646
Other liabilities
8,919
9,337
Working capital
39 091
38 383
Shareholders’ equity
23 136
8 496
8 680
6 586
6 567
39 091
38 383
- Excluding assets included in net debt; 2. Net of cash, cash equivalents, marketable securities, other short-term investments and financial instrument asset
42
NET DEBT
Reported Net
Debt/EBITDA
REPORTED: -€0.2bn
€8.6bn
+1.5
2.0x
€8.4bn
+0.5
-0.2
+0.8
-2.8
Net Debt
31/12/2024
FCF
M&A
Dividends
Share Buyback1
Others2
- To offset the dilutive impact of employee shareholder plans; 2. Includes +€0.3 bn new leases on the period, -€0.5 bn of new hybrid financing
Net Debt
31/12/2025
43
DISCLAIMER
This presentation contains certain forward-looking statements concerning Danone that are subject to risks and uncertainties. In
some cases, you can identify these forward-looking statements by forward-looking words, such as “estimate”, “expect”,
“anticipate”, “project”, “plan”, “intend”, “objective”, “believe”, “forecast”, “guidance”, “outlook”, “foresee”, “likely”, “may”,
“should”, “goal”, “target”, “might”, “will”, “could”, “predict”, “continue”, “convinced” and “confident,” the negative or plural of
these words and other comparable terminology, or by using future dates. Forward looking statements in this document include,
but are not limited to, predictions of future activities, operations, direction, performance and results of Danone.
These forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ
materially from those anticipated in these forward-looking statements. For a description of these risks and uncertainties, please
refer to the “Risk Factors” sections of Danone’s Universal Registration Document (the current version of which is available on
www.danone.com).
Subject to regulatory requirements, Danone does not undertake to publicly update or revise any of these forward-looking
statements. This document does not constitute an offer to sell, or a solicitation of an offer to buy Danone securities.
All references in this presentation to Like-for-like (LFL) changes in sales, margin from operations, recurring operating income,
recurring operating margin, other non-recurring financial income and expense, non-recurring income tax, recurring effective tax
rate, non-recurring share of profit (loss) of equity-accounted companies, recurring net income, recurring EPS, free cash flow,
working capital/sales, net financial debt, net debt/EBITDA, ROIC and payout ratio correspond to financial indicators not defined
in IFRS. Please refer to the financial press releases issued by the Company for further details on IAS29 (Financial reporting in
hyperinflationary economies), the definitions and reconciliation with financial statements of financial indicators not defined in
IFRS.
Due to rounding, the sum of values presented in this presentation may differ from totals as reported. Such differences are not
material.
Photo credits: Cover page with Carlos Alcaraz, image courtesy of Tennis Australia / Fiona Hamilton; Photo By Tennis Australia /
Morgan Hancock
44